FIDELIO-DKD
Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 5,734 patients with type 2 diabetes and CKD, finerenone reduced the composite of kidney failure, ≥40% eGFR decline or renal death compared with placebo.
N
5 734
Schéma
Double-blind RCT, median 2.6-year follow-up
Critère
Kidney failure, ≥40% eGFR decline, or renal death
Pertinence
1
Résultat17.8% vs 21.1%; HR 0.82 (95% CI 0.73–0.93; p=0.001).
Bakris GL, et al. N Engl J Med. 2020;383(23):2219-2229. 10.1056/NEJMoa2025845
Discussion et critique
Established the nonsteroidal MRA as renoprotective; hyperkalaemia-related discontinuation 2.3% vs 0.9%.